Viral vectors and vaccines navigate public distrust while advancing through AI design, COVID response lessons, and promising ...
Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...
From rare diseases to common chronic conditions, advances in viral vector-based gene therapies are bringing exciting new clinical possibilities to the table. But current costs per dose land as high as ...
Viral vector manufacturing continues to face challenges in delivering consistent quality and achieving high productivity at scale. This webinar will highlight how CDMO innovation drives improvements ...
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best mid cap growth stocks to invest in now. Earlier on June 4, Sarepta Therapeutics announced that the US FDA has granted Platform Technology ...
COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organization (CDMO) for viral vectors, announced today the successful ...
The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy candidate SRP-9003 for limb-girdle muscular dystrophy type 2E/R4 (LGMD2E/R4), ...
James Miskin brings 25 years of cell and gene therapy experience to an advisory role focused on further unlocking ViroCell’s potential LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results